Europe Pneumococcal Vaccine Market Size study, by Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine) by Product (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Products) by End-use (Public Sector, Privat

Europe Pneumococcal Vaccine Market Size study, by Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine) by Product (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Products) by End-use (Public Sector, Private Sector) and Country Forecasts 2022-2032

Europe Pneumococcal Vaccine Market is valued approximately USD 1.23 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.84% over the forecast period 2024-2032. The Pneumococcal Vaccine is a vaccine that prevents against infection with Streptococcus pneumoniae bacteria, also known as pneumococcus. This bacterium can cause pneumonia, meningitis, and bacteremia. The vaccination works by stimulating the immune system to produce antibodies against certain bacterial strains, preventing infection. Also, continuous advancements in vaccine technology have led to the development of improved pneumococcal vaccines with enhanced efficacy and safety profiles. This has further stimulated market growth as healthcare providers and patients opt for newer and more effective vaccines. Thus, this trend is anticipated to support the growth of Europe Pneumococcal Vaccine Market.

Moreover, growing awareness among healthcare professionals and the general public about the importance of pneumococcal vaccination in preventing pneumonia and other pneumococcal diseases drives the demand for vaccines. Also, government initiatives and vaccination programs aimed at preventing pneumococcal diseases among infants, children, and older adults contribute significantly to market growth. These initiatives often include free or subsidized vaccination programs, increasing accessibility and affordability. Additionally, the increasing incidence of pneumococcal diseases, such as pneumonia, meningitis, and septicemia, particularly among vulnerable populations such as infants, elderly individuals, and those with weakened immune systems, fuels the demand for pneumococcal vaccines. However, the stringent regulatory processes and approval requirements are expected to hinder the Europe Pneumococcal Vaccine market growth during the forecast period 2024-2032.

The key countries considered for the Europe Pneumococcal Vaccine market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany was the largest market in terms of revenue. the rising incidences of pneumococcal diseases, such as pneumonia, meningitis, and sepsis, have propelled the demand for pneumococcal vaccines. With a growing elderly population and individuals with chronic diseases who are more susceptible to pneumococcal infections, there's a heightened awareness regarding preventive measures such as vaccination. Whereas, the United Kingdom is expected to grow with the highest CAGR during the forecast period 2024-2032.

Major market player included in this report are:
GSK plc
Sanofi SE
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Vaccine Type
Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine

By Product
Prevnar 13
Synflorix
Pneumovax 23
Vaxneuvance
Pneumosil
Other Products

By End-use
Public Sector
Private Sector
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.